Key result
Novel CD68-targeted contrast agent enables dual US and MRI detection of plaque macrophages.
Macrophage recruitment has emerged as the crucial force driving the initiation and progression of atherosclerotic lesions. Therefore, the identification of macrophages in plaques is of vital importance for identifying vulnerable plaques, and noninvasive imaging methods are particularly desirable. Some studies have reported that MRI can detect plaque macrophages through targeted nanoparticles, but it is still hard for an US to detect macrophages in atherosclerotic plaque. In this study, anti-CD68 receptor-targeted Fe-doped hollow silica nanoparticles (CD68-Fe-HSNs) were fabricated as a dual-modal US/MRI contrast agent for identifying macrophages of aorta ventralis atherosclerotic plaques in ApoE-/- mice, confirmed by immunofluorescence and bio-TEM. This system possesses biodegradable characteristics even though it is an inorganic mesoporous nanosystem, indicating its potential high biocompatibility for further in vivo research. We expect that these dual-modal US/MRI nanoparticles will play a role in assessing vulnerable plaque in future research studies.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2018) studied Atherosclerotic plaques. Anti-CD68 receptor-targeted Fe-doped hollow silica nanoparticles (CD68-Fe-HSNs) was evaluated on Identification of macrophages in aorta ventralis atherosclerotic plaques via dual-modal US/MRI. Biodegradable CD68-Fe-HSNs served as a dual-modal US/MRI contrast agent to identify macrophages in aorta ventralis atherosclerotic plaques of ApoE-/- mice.
Synapse has enriched 5 related papers. Consider them for comparative context: